Compare Oscar Health Inc (OSCR) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oscar Health Inc vs Trip.com Group Ltd — how do they compare? Oscar Health Inc trades at $31.71 (market cap $10.19B), while Trip.com Group Ltd trades at $39.2 (market cap $26.04B). The key difference: Trip.com Group Ltd is far larger — about 2.6× Oscar Health Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals.
| OSCR | TCOM | |
|---|---|---|
Market Cap | $10.19B | $26.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $33.01 | $78.96 |
52-Week Low | $10.85 | $39.19 |
Enterprise Value | $6.54B | $18.64B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oscar Health (OSCR) trades at $33.01, up 2.36% today and approaching its 52-week high of $33.10. The stock shows strong technical momentum with bullish moving averages and has surged 109% year-to-date. Fundamentally, revenue grew from $11.7B in 2025 to $15.3B in 2026, with net income turning positive at $551M. Recent earnings beats and membership growth to 2.96 million support the bullish case, though valuation metrics like P/E of 25.39 and P/B of 4.97 suggest premium pricing.
Outlook remains positive with strong revenue growth and profitability improvements, but risks include high valuation multiples and dependence on sustained membership growth. Analyst consensus is mixed with 27% buy ratings and a $30.67 price target below current levels, indicating caution despite technical strength. Key catalysts include continued operational efficiency gains and AI integration, while medical cost management remains critical.
Trip.com (TCOM) trades at $40.50, down 1.29% with bearish technical signals despite strong fundamentals. The company reported robust 2025 results with $62.41B revenue and 53.34% net margin, though recent quarters show earnings misses. Valuation metrics appear attractive with P/E of 6.01 and EV/EBITDA of 3.21. However, the stock faces headwinds from a recent $770M Chinese antitrust penalty and declining cash flow trends.
The investment case balances deep value against regulatory risks. Analyst consensus remains bullish with $59.29 price target (47% upside), but technical weakness and China regulatory overhang create near-term uncertainty. Long-term growth prospects in travel recovery support the bull case, though investors should monitor Q2 2026 earnings due September 15 for confirmation of business momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
